VivoSim Labs (VIVS) Competitors $1.81 +0.04 (+2.26%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock VIVS vs. FNCH, IMNN, BCAB, ATNF, CMMB, HOTH, ASBP, CVKD, PASG, and SYBXShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include Finch Therapeutics Group (FNCH), Imunon (IMNN), BioAtla (BCAB), 180 Life Sciences (ATNF), Chemomab Therapeutics (CMMB), Hoth Therapeutics (HOTH), Aspire Biopharma (ASBP), Cadrenal Therapeutics (CVKD), Passage Bio (PASG), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors Finch Therapeutics Group Imunon BioAtla 180 Life Sciences Chemomab Therapeutics Hoth Therapeutics Aspire Biopharma Cadrenal Therapeutics Passage Bio Synlogic VivoSim Labs (NASDAQ:VIVS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Which has more risk and volatility, VIVS or FNCH? VivoSim Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Which has preferable valuation and earnings, VIVS or FNCH? VivoSim Labs has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivoSim Labs$140K33.61-$2.48M-$10.20-0.18Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.44 Does the media refer more to VIVS or FNCH? In the previous week, VivoSim Labs had 7 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 7 mentions for VivoSim Labs and 0 mentions for Finch Therapeutics Group. VivoSim Labs' average media sentiment score of 0.45 beat Finch Therapeutics Group's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media. Company Overall Sentiment VivoSim Labs Neutral Finch Therapeutics Group Neutral Is VIVS or FNCH more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets VivoSim Labs-1,396.48% -32.95% -21.31% Finch Therapeutics Group N/A -69.14%-26.92% Do insiders and institutionals have more ownership in VIVS or FNCH? 8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 3.7% of VivoSim Labs shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryVivoSim Labs beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.71M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.1820.7630.8625.25Price / Sales33.61231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book0.339.759.516.00Net Income-$2.48M-$54.74M$3.26B$265.34M7 Day Performance1.69%8.09%4.49%2.81%1 Month Performance-4.23%7.70%5.18%1.50%1 Year PerformanceN/A18.13%31.98%25.46% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim LabsN/A$1.81+2.3%N/AN/A$4.71M$140K-0.1820Earnings ReportGap UpFNCHFinch Therapeutics GroupN/A$12.29-1.4%N/A-1.9%$19.74MN/A-1.39190IMNNImunon1.5234 of 5 stars$8.76-4.8%$232.50+2,554.1%-62.6%$19.53M$500K-0.4330Gap UpBCABBioAtla2.3152 of 5 stars$0.35+5.6%$5.00+1,328.6%-80.6%$19.37M$11M-0.2960Gap UpATNF180 Life Sciences0.4994 of 5 stars$3.36+5.7%N/A+291.1%$19.20MN/A-0.227Gap DownCMMBChemomab Therapeutics3.4558 of 5 stars$0.97-3.0%$8.50+776.3%-16.2%$18.86MN/A-1.2820Earnings ReportUpcoming EarningsShort Interest ↓Gap UpHOTHHoth Therapeutics3.056 of 5 stars$1.38-1.4%$4.00+189.9%+81.8%$18.49MN/A-1.214Earnings ReportAnalyst ForecastShort Interest ↓ASBPAspire BiopharmaN/A$0.35-3.0%N/AN/A$18.06MN/A0.00N/ANews CoverageEarnings ReportGap UpCVKDCadrenal Therapeutics2.9296 of 5 stars$10.90+23.7%$32.00+193.6%N/A$18.03MN/A-1.184Earnings ReportShort Interest ↑High Trading VolumePASGPassage Bio3.7715 of 5 stars$5.81+1.2%$150.00+2,481.8%-54.5%$17.91MN/A-0.28130Earnings ReportAnalyst RevisionGap UpSYBXSynlogic0.9571 of 5 stars$1.40-6.7%N/A+2.8%$17.54M$10K-0.5680Short Interest ↑ Related Companies and Tools Related Companies Finch Therapeutics Group Alternatives Imunon Alternatives BioAtla Alternatives 180 Life Sciences Alternatives Chemomab Therapeutics Alternatives Hoth Therapeutics Alternatives Aspire Biopharma Alternatives Cadrenal Therapeutics Alternatives Passage Bio Alternatives Synlogic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access